Cargando…
Disease-Modifying Therapy for Transthyretin Amyloidosis: Where to Start? Where to Stop?
Autor principal: | Fine, Nowell M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299765/ https://www.ncbi.nlm.nih.gov/pubmed/34317122 http://dx.doi.org/10.1016/j.jaccas.2020.10.004 |
Ejemplares similares
-
Rare Cardiovascular Disease Care: Centers of Excellence or Excellence of Centers?
por: Fine, Nowell M., et al.
Publicado: (2023) -
Juggling While Dancing: The Complex Medical Management of Heart Failure With Reduced Ejection Fraction
por: Fine, Nowell M., et al.
Publicado: (2021) -
TTR Amyloidosis: Current State of Affairs and Promise for the Future
por: Brailovsky, Yevgeniy, et al.
Publicado: (2023) -
Protocols for the obvious: Where does it start, and stop?
por: Girbes, Armand R. J., et al.
Publicado: (2017) -
Where functional MRI stops, metabolism starts
por: Frangou, Polytimi, et al.
Publicado: (2022)